Treating Wet Age-Related Macular Degeneration and Diabetic Macular Edema

Philip Niles, MD, MBA, and Nicholas G. Anderson, MD, define wet age-related macular degeneration (AMD) and review clinical manifestations of the disease.

Nicholas G. Anderson, MD, and Philip Niles, MD, MBA, provide an overview of diabetic macular edema (DME) and the impact of vision impairment on a patient’s quality of life.

Kevin U. Stephens, Sr., JD, MD, leads a discussion exploring the key drivers of cost for patients with wet age-related macular degeneration (AMD).

Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; Jim Kenney, RPh, MBA; and Nicholas G. Anderson, MD, review goals of therapy for patients with wet age-related macular degeneration (AMD) and discuss a health plan perspective for the management of therapy.

Nicholas G. Anderson, MD; Philip Niles, MD, MBA; and Kevin U. Stephens, Sr., JD, MD, provide insight on the anti-VEGF treatment landscape and options for patients with wet AMD and DME.

Philip Niles, MD, MBA, leads a discussion on treatment approaches that are utilized with anti-VEGF agents in wet AMD and DME, including payer considerations for approaches such as treat and extend.

Nicholas G. Anderson, MD, shares factors to consider when selecting an anti-VEGF agent for treatment of wet AMD and DME.

Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; Nicholas G. Anderson, MD; and Jim Kenney, RPh, MBA, comment on managing the utilization of anti-VEGF agents for wet AMD and DME, including the impact of step edits on care.

Philip Niles, MD, MBA; Jim Kenney, RPh, MBA; and Nicholas G. Anderson, MD, discuss the clinical and economic implications of a delay in therapy for wet AMD and DME.

Nicholas G. Anderson, MD, explores the use of a novel port delivery system with ranibizumab for the treatment of wet AMD.

Philip Niles, MD, MBA; Nicholas G. Anderson, MD; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, comment on safety and cost considerations for the uptake of anti-VEGF biosimilars such as ranibizumab and discuss the impact on the future treatment landscape for wet AMD.

Nicholas G. Anderson, MD, leads a discussion on how the first ophthalmic formulation of bevacizumab may impact the wet AMD treatment paradigm.

Philip Niles, MD, MBA; Nicholas G. Anderson, MD; and Kevin U. Stephens, Sr., JD, MD, explore the role of faricimab in the current treatment landscape for wet AMD.

Nicholas G. Anderson, MD; Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, provide insight on unmet needs and future directions for the treatment of wet AMD and DME.